Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

451

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

451 results for “AMD”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD

ClinicalTrials.gov study NCT00469352. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

ClinicalTrials.gov study NCT01024998. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

VITAL - Individualising Therapy for Neovascular AMD With Aflibercept

ClinicalTrials.gov study NCT02441816. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Transplantation of Autologous RPE Versus Translocation of Autologous RPE and Choroid in AMD

ClinicalTrials.gov study NCT00401713. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD

ClinicalTrials.gov study NCT04676854. IPD Sharing: NO. Countries: 6. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

ClinicalTrials.gov study NCT00470678. IPD Sharing: Not stated. Countries: 2. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

ADVM-022 Intravitreal Gene Therapy for Wet AMD

ClinicalTrials.gov study NCT03748784. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD

ClinicalTrials.gov study NCT00684853. IPD Sharing: Not stated. Countries: 1. Publications: 12.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad32/100

Data from: Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD

Open the record for dataset details and reuse information.

publicAug 2019View details →
dryad28/100

Data from: The Moorfields AMD database report 2 - fellow eye involvement with neovascular age-related macular degeneration

<p><b>Background/Aims:</b> Neovascular age-related macular degeneration (nAMD) is frequently bilateral, and previous reports on 'fellow eyes'' have assumed sequential treatment after a period of treatment of the first eye only. The aim of our study was to analyse baseline characteristics and visual acuity (VA) outcomes of fellow eye involvement with nAMD, specifically differentiating between sequential and non-sequential (due to macular scarring in the first eye) anti-vascular endothelial growth factor treatment and timelines for fellow eye involvement.</p> <p><b>Methods:</b> Retrospective, electronic medical record database study of the Moorfields AMD database of 6265 patients /120,286 single entries with data extracted between October 21, 2008 and August 9, 2018. The dataset for analysis consisted of 1180 sequential, 807 nonsequential, and 3410 unilateral eyes.</p> <p><b>Results: </b>Mean VA (Early Treatment Diabetic Retinopathy Study letters±SD) of sequentially treated fellow eyes at baseline was significantly higher (63±13), VA gain over two years lower (0.37±14), and proportion of eyes with good VA (≥70 letters) higher (46%) than the respective first eyes (baseline VA 54±16, VA gain at two years 5.6±15, percentage of eyes with good VA 39%). Non-sequential fellow eyes showed baseline characteristics and VA outcomes similar to first eyes. Fellow eye involvement rate was 32% at two years, and median time interval to fellow eye involvement was 71 (IQR 27-147) weeks.</p> <p><b>Conclusion:</b> This report shows sequentially treated nAMD fellow eyes have better baseline and final VA than non-sequentially treated eyes after 2 years of treatment. Sequentially treated eyes also had a greater proportion with good VA after 2 years.</p>

opencc-zeroSep 2019View details →
zenodo28/100

Supplementary information for "GROMACS on AMD GPU-Based HPC Platforms: Using SYCL for Performance and Portability"

<p>GROMACS inputs for the performance benchmarks in the manuscript.</p>

opencc-by-4.0Apr 2024View details →
zenodo28/100

Dataset: GraniteShares 2x Long AMD Daily ETF (AMDL) Stock Performance

This dataset provides historical stock market performance data for specific companies. It enables users to analyze and understand the past trends and fluctuations in stock prices over time. This information can be utilized for various purposes such as investment analysis, financial research, and market trend forecasting.

opencc-zeroJun 2024View details →
zenodo28/100

SCHEDA HTA AMDS

<p>SCHEDA HTA AMDS</p>

opencc-by-4.0Jul 2021View details →
ClinicalTrials.gov28/100

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

ClinicalTrials.gov study NCT02461771. IPD Sharing: Not stated. Countries: 2. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Ranibizumab and Reduced Fluence PDT for AMD

ClinicalTrials.gov study NCT00527475. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

ClinicalTrials.gov study NCT01722045. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD

ClinicalTrials.gov study NCT01819415. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

ClinicalTrials.gov study NCT02684578. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Cataract and AMD in a Trial of a Multivitamin and Cocoa Extract

ClinicalTrials.gov study NCT03205202. IPD Sharing: UNDECIDED. Countries: 0. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)

ClinicalTrials.gov study NCT00407719. IPD Sharing: Not stated. Countries: 0. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record